Parallel Advisors’s IGM Biosciences IGMS Stock Holding History

Parallel Advisors’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13	Closed	-$221	–	3459
2022 Q4	$221	Hold	13	–	–	﹤0.01%	3174
2022 Q3	$0	Buy	+13	New	+$262	﹤0.01%	3309
2022 Q1	–	Sell	-70	Closed	-$2K	–	3100
2021 Q4	$2K	Buy	70 +66	+1,650%	+$3.28K	﹤0.01%	2703
2021 Q3	$0	Buy	+4	New	+$306	﹤0.01%	3155

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Parallel Advisors's IGMS Position: Q1 2023 in Review

Parallel Advisors sold out of IGM Biosciences (IGMS) in Q1 2023, closing a stake of 13 shares — an estimated $221 sold.

Parallel Advisors first reported a position in IGMS in Q3 2021 and held it in 4 quarters. The position peaked at $2K in Q4 2021. 74 funds tracked by Wall St. Rank hold IGMS as of Q1 2023.

Parallel Advisors reported no remaining IGM Biosciences position as of Q1 2023 after selling out during the quarter.
Parallel Advisors sold 13 IGM Biosciences shares in Q1 2023, an estimated $221.
Parallel Advisors first reported a position in IGM Biosciences in Q3 2021 and held it in 4 quarters.
Parallel Advisors's IGM Biosciences position peaked at $2K in Q4 2021.
74 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2023.

Based on Parallel Advisors's 13F filing for Q1 2023, filed 25 Apr 2023.